Monday 11 July

12.00-14.00      Registration


14.00-14.20      Opening: welcome by Frank Redegeld (Utrecht, The Netherlands) and Francesca Levi-Schaffer (Jerusalem, Israel)


14.20-16.15      Session 1: Novel insights in mast cell/basophil development

                        Chairs: Jenny Hallgren and Joana Vitte  


14.20-15.15      Blueprint key note lecture 1: Developmental Origin of Mast Cells

Florent Ginhoux (Singapore, Singapore)


15.15-15.35      Single-cell molecular of basophil and mast cell development

Joakim Dahlin (Stockholm, Sweden)


15.35-15.55      Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation

Thomas Plum (Heidelberg, Germany)


15.55-16.15      Changes in molecular phenotypes and cell-cell interactions of mast cells in disease revealed by single-cell transcriptomics

Martijn Nawijn (Groningen, The Netherlands)                                        


16.15-16.45      Coffee break    


16.45-17.45      Oral abstract session 1: big data in mast cell/basophil development     

Chairs: Hanneke Oude Elberink and Gunnar Nilsson


16.45-16.57      Investigating haematopoiesis of aberrant and normal mast cells through single-cell multi-omics

                        Daryl Zhong Hao Boey (Solna, Sweden)


16.57-17.09      Single-cell transcriptomics reveals the identity and regulators of human mast cell progenitors     

                        Chenyan Wu (Solna, Sweden)


17.09-17.21      Adult mast cell development critically depends on mitochondrial fusion

                        Manuel Stecher (Freiburg, Germany)


17.21-17.33      Deciphering human mast cell differentiation by CRISPR/Cas9

                        Jiezhen Mo (Solna, Sweden)


17.33-17.45      Cytoskeletal mechanisms organizing tissue-resident mast cell networks

                        Tim Lämmermann (Freiburg, Germany)


17.45-19.45      Poster session 1 + network reception

Tuesday 12 July

Tuesday July 12th, 2022

08.00-08.45      Board meeting EMBRN


9.00-11.35        Session 2: Mast cells in health and disease

Chairs: Marcus Maurer and Frank Redegeld


09.00-09.30      Introductory lecture: How mast cells make us sick – mechanisms of mast cell activation in mast cell driven diseases                    

                        Laurent Reber (Toulouse, France)


09.30-10.15      Cogent Biosciences key note lecture 2: Mast Cells in Irritable Bowel Syndrome

Guy Boeckxstaens (Leuven, Belgium)


10.15-10.30      Short break


10.30-10.50      Mast cells in cardiovascular diseases

Ilze Bot (Leiden, The Netherlands)


10.50-11.10      Mast cell nerve interactions and MRGPRX2

Nicolas Gaudenzio (Toulouse, France)


11.10-11.20      Mast cell disorders

Frank Siebenhaar (Berlin, Germany)


11.20-12.00      Coffee break


12.00-13.00      Oral abstract session 2: Mechanisms of mast cell activation, mast cells in disease                      Chairs: Ilze Bot and Ulrich Blank            


12.00-12.12      Rab44 regulates MC-driven anaphylaxis through kinesin-1-dependent secretory granule translocation

                        Gaël Ménasché (Paris, France)


12.12-12.24      Insulin-Regulated Aminopeptidase (IRAP) sets the intensity of FcR-mediated inflammation

                      Shamila Vibhushan (Paris, France)


12.24-12.36      Substance P targets MRGPRX2 to the secretory granules by autophagy-aided macropinocytosis

                        Pia Lazki-Hagenbach (Tel Aviv, Israel)


12.36-12.48      Impact of ageing on the severity of IgE-, Mrgprb2-, and histamine-mediated anaphylaxis in mice

                        Jasper Kamphuis (Toulouse, France)


12.48-13.00      Age-induced mast cell activation and antigen presentation in atherosclerosis

                        Marie Depuydt (Leiden, The Netherlands)


13.00-14.00      Lunch including “Meet the Professor”


14.00-15.45      Session 3: Novel strategies in mast cell research, therapy & diagnostics

Chairs: Edward Knol and Frank Siebenhaar


14.00-14.45      Key note lecture 3: Novel strategies to actively desensitize allergic effector cells             

Alexander Eggel (Bern, Switzerland)


14.45-15.05      Identification of mast cell degranulation regulators using functional genomics and single-cell imaging

Jelle Folkerts (Stanford, USA)


15.05-15.25      Biomarkers of diagnosis and resolution of allergy

Alexandra Santos (London, UK)


15.25-15.45      New mast cell therapies on the horizon

Martijn van Doorn (Rotterdam, the Netherlands)


15.45-16.15      Coffee break    


16.15-17.15      Oral abstract session 3: Novel strategies in mast cell research, therapy & diagnostics                            

Chairs: Jelle Folkerts and Philip Starkl


16.15-16.27      Elevated sFcεRI predicts early response to omalizumab treatment in chronic spontaneous urticarial

                        Sherezase Moñino-Romero (Berlin, Germany)


16.27-16.39      Effective anti-melanoma immune response by peritumoral delivery of the heat shock protein 70 (Hsp70)

                        Suzanne Kaesler (Munich, Germany)


16.39-16.51      Siglec-6 Interacts with KIT/CD117, Recruits Shp Phosphatases and Inhibits SCF-mediated Inflammation

                        Wouter Korver (San Carlos, United States)


16.51-17.03      Mast cell-derived FXIIIA contributes to sexual dimorphic defense against Group B Streptococcus

                        Adrian Piliponsky (Seattle, United States)


17.03-17.15      Salt-Inducible Kinases (SIKs): Recently identified regulators of mast cell function

                        Nicola Darling (Dundee, United Kingdom)


17.15-18.45      Poster session 2 + drinks          


19.00-24.00      Social event                  Drinks/Food/Music     


Gasthuis Leewenbergh

Servaasbolwerk 1a
3512 NK Utrecht

Wednesday 13 July

Wednesday July 13th, 2022

08.00-08.45      EMBRN assembly: plenary meeting of EMBRN members, Board Update


09.00- 10.45     Session 4: Joint session EMBRN/International Eosinophil Society

Chairs: Florence Roufosse and Francesca Levi-Schaffer


09.00-09.40      Key note lecture 4: The Allergic Effector Unit and its new druggable targets                               

Francesca Levi-Schaffer (Jerusalem, Israel)


09.40-09.45      Introduction by Florence Roufosse and Francesca Levi-Schaffer


09.45-10.20      Eosinophils, mast cells and Siglecs: from biology to drug target

Bruce Bochner (Chicago, USA)


10.20-10.45       Eosinophil kinetics in health and disease

Leo Koenderman (Utrecht, The Netherlands)


10.45-11.10      Coffee break    


11.10-12.25      Oral abstract session 4: Interactions between mast cells, eosinophils and other immune cells.  

Chairs: Bernhard Gibbs and Maud Hermans


11.10-11.25      The Role of Mast Cells, Eosinophils and Basophils in Pemphigoid Diseases

Bernhard Gibbs (Oldenburg, Germany)


11.25-11.37      Bidirectional activation of human skin mast cells and blood eosinophils

Stefan Frischbutter (Berlin, Germany)


11.37-11.49      CT-M8 : a new mouse model reveals the non-redundant role of basophils in lupus-like disease onset

John Tchen (Paris, France)


11.49-12.01      Mast cell granules are endogenous CLR ligands skewing DC function towards TH2/TH17 response

                        Johanna Kotrba (Magdeburg, Germany)


12.01-12.13      Mast cells trap and cannibalize swarming neutrophils for metabolic and inflammatory fueling

                        Michael Mihlan (Freiburg, Germany)


12.13-12.25      T helper-licensed mast cells promote inflammatory Th17/Treg cells imbalance

Edouard Leveque (Toulouse, France)


12.25-12.45      Prizes for best poster/oral presentations and farewell by Frank Redegeld